Year All2026202520242023202220212020 March 25, 2026 Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read More March 18, 2026 Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call Read More March 9, 2026 Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology Read More February 25, 2026 Celcuity To Participate in Upcoming Investor Conferences Read More February 12, 2026 Celcuity Appoints Charles Romp to its Board of Directors Read More February 4, 2026 Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 Read More January 20, 2026 Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer Read More
March 25, 2026 Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read More
March 18, 2026 Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call Read More
March 9, 2026 Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology Read More
February 4, 2026 Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 Read More
January 20, 2026 Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer Read More